HDAC9 and AL amyloidosis: Although several pan-HDAC inhibitors (e.g., vorinostat, romidepsin, and panobinostat) are currently in clinical use, those drugs were mainly approved for cutaneous T-cell lymphoma (CTCL) or multiple myeloma therapy instead of solid tumors [33,34,35].